Literature DB >> 20101064

Bioavailability in healthy adults of efavirenz capsule contents mixed with a small amount of food.

Sanjeev Kaul1, Ping Ji, Michael Lu, Kim L Nguyen, Tong Shangguan, Dennis Grasela.   

Abstract

PURPOSE: The effect of mixing the contents of efavirenz capsules (sprinkles) with a small amount of food on the bioavailability and pharmacokinetics of efavirenz in healthy adults was evaluated.
METHODS: In a randomized, three-period, crossover study, 24 healthy adult subjects were divided equally into two groups. Group I received treatments A, B, and C, and those in group II received treatments A, D, and E. Treatment A was three efavirenz 200-mg intact capsules under fasting conditions. Treatments B, C, D, and E were three efavirenz 200-mg capsule contents mixed with two teaspoons of applesauce, grape jelly, yogurt, or infant formula, respectively. A single dose was given on days 1, 21, and 41. The steady-state mean maximum observed concentration, time of maximum observed concentration, area under the concentration-time curve (AUC) half-life, taste, and safety were assessed.
RESULTS: The AUC after administration of a single 600-mg dose of efavirenz sprinkles mixed with two teaspoons of any of the food vehicles to healthy adults was bioequivalent to a 600-mg efavirenz dose given as intact capsules under fasting conditions. Subjects rated efavirenz mixed with grape jelly as the most palatable. Adverse events and laboratory abnormalities were similar for all treatments.
CONCLUSION: The AUC of efavirenz 600 mg administered as capsule sprinkles with two teaspoons of applesauce, grape jelly, yogurt, or infant formula was bioequivalent to a single dose of efavirenz 600 mg given as intact capsules under fasting conditions in healthy adults.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20101064     DOI: 10.2146/ajhp090327

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  6 in total

1.  The effect of malnutrition on the pharmacokinetics and virologic outcomes of lopinavir, efavirenz and nevirapine in food insecure HIV-infected children in Tororo, Uganda.

Authors:  Imke H Bartelink; Rada M Savic; Grant Dorsey; Theodore Ruel; David Gingrich; Henriette J Scherpbier; Edmund Capparelli; Vincent Jullien; Sera L Young; Jane Achan; Albert Plenty; Edwin Charlebois; Moses Kamya; Diane Havlir; Francesca Aweeka
Journal:  Pediatr Infect Dis J       Date:  2015-03       Impact factor: 2.129

2.  Acceptable plasma concentrations of raltegravir and etravirine when administered by gastrostomy tube in a patient with advanced multidrug-resistant human immunodeficiency virus infection.

Authors:  Uriel Sandkovsky; Susan Swindells; Ryan Moore; Edward P Acosta; Courtney V Fletcher
Journal:  Pharmacotherapy       Date:  2012-02       Impact factor: 4.705

3.  Establishing Dosing Recommendations for Efavirenz in HIV/TB-Coinfected Children Younger Than 3 Years.

Authors:  Mutsa Bwakura Dangarembizi; Pearl Samson; Edmund V Capparelli; Carolyn Bolton Moore; Patrick Jean-Philippe; Stephen A Spector; Nahida Chakhtoura; Alex Benns; Bonnie Zimmer; Lynette Purdue; Chivon Jackson; Carole Wallis; Jennifer L Libous; Ellen G Chadwick
Journal:  J Acquir Immune Defic Syndr       Date:  2019-08-01       Impact factor: 3.731

4.  Pharmacokinetics of lopinavir/ritonavir and efavirenz in food insecure HIV-infected pregnant and breastfeeding women in Tororo, Uganda.

Authors:  Imke H Bartelink; Rada M Savic; Julia Mwesigwa; Jane Achan; Tamara Clark; Albert Plenty; Edwin Charlebois; Moses Kamya; Sera L Young; Monica Gandhi; Diane Havlir; Deborah Cohan; Francesca Aweeka
Journal:  J Clin Pharmacol       Date:  2013-09-21       Impact factor: 3.126

5.  Antiretroviral treatment in HIV-1 infected pediatric patients: focus on efavirenz.

Authors:  Beatriz Larru; Jessica Eby; Elizabeth D Lowenthal
Journal:  Pediatric Health Med Ther       Date:  2014-05-29

6.  Population Pharmacokinetics Analysis To Inform Efavirenz Dosing Recommendations in Pediatric HIV Patients Aged 3 Months to 3 Years.

Authors:  Man Luo; Sunny Chapel; Heather Sevinsky; Ishani Savant; Brenda Cirincione; Richard Bertz; Amit Roy
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.